For example, hepatic steatosis is a complex process that may involve different nuclear receptors, including AHR, CAR, PXR, PPARα, and others, with the nuclear receptor interaction constituting the molecular initiating events in the adverse outcome pathway for liver steatosis, as for example shown in [58]. This evidence concerns the gene NR1I2 and fatty liver disease.